Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer

Kidney Cancer · Published 2022-07-20 · DOI 10.3233/kca-229003

Authors being retrieved — see the publisher record. https://doi.org/10.3233/kca-229003

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2022

Related articles

• Spatial clustering of immunosuppressive macrophages in papillary renal cell carcinoma · Kidney Cancer · 2025 · Same journal
• Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023 · Kidney Cancer · 2024 · Same journal
• Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy · Kidney Cancer · 2024 · Same journal
• Clinical Trials Corner: The dreaded IVC thrombus - optimizing management · Kidney Cancer · 2024 · Same journal
• Comparison of Oncological and Functional Outcomes of Radical Versus Partial Nephrectomy for cT1b Renal Cell Carcinoma: A Two-Centre, Matched Analysis · Kidney Cancer · 2024 · Same journal
• Retrospective Study of Real-World Treatment Patterns and Outcomes in Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Lenvatinib/Everolimus after Heavy Pretreatment · Kidney Cancer · 2021 · Same journal
• Clinical Trials Corner: Another Approach to Treatment of Advanced Papillary Renal Cell Carcinoma · Kidney Cancer · 2022 · Same journal
• Efficacy of Therapy vs Surveillance in Patients with Resected Early-Stage Intermediate to High-Risk Renal Cell Carcinoma · Kidney Cancer · 2023 · Same journal
• “PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer · Kidney Cancer · 2021 · Same journal
• Hereditary Renal Cell Carcinoma · Kidney Cancer · 2022 · Same journal